Brits to trial bird flu vaccine on humans

	Tweet

The British drug company PowderMed has applied for permission to conduct the first trial in Britain of a vaccine against the avian flu virus.

The company which is based in Oxford, has asked the Medicines and Healthcare products Regulatory Agency (MHRA) for clearance to test its H5N1 vaccine on 75 volunteers at Guy’s Hospital in London.

The lethal H5N1 strain of avian flu has spread rapidly throughout bird populations in Asia and into Europe by flocks of migrating waterfowl.

To date the World Health Organisation has reported 97 human cases of avian flu since December 2003, with at least 53 deaths and the long standing fear has been that the lethal H5N1 strain of the virus might mutate into a form easily transmissible between humans, potentially triggering a worldwide pandemic.

The MHRA is expected to grant approval for the trial to proceed.

Any effective vaccine against avian flu would considerably augment efforts to limit the infection’s spread if a pandemic strain emerges, by supplementing the government stockpiles of the anti-viral drugs Tamiflu and Relenza.

The proposed vaccine differs from conventional vaccines in that it is based on weakened strains or fragments of the virus and can be produced quickly and cheaply.

Volunteers in the trial will be subjected to an alternative to the needle jab and will get instead a handheld device which will blast harmless, microscopic gold particles coated in the vaccine into the upper arm at supersonic speeds.

Tests earlier this year of a DNA vaccine designed to give protection against seasonal flu showed that it offered 100% protection, based on the immune response of volunteers.

The DNA vaccine against avian flu as yet has only been tested in animals, where it has also proved successful.

John Beadle, the chief medical officer at PowderMed, said that it would be possible to create a new vaccine in about ten weeks, much more quickly than traditional vaccines, which are developed in hens’ eggs.

Research suggests two doses of the vaccine, a prime and a booster will be needed to give adequate protection.

Details of the trial can be found on the U.S. Government’s website, Clinicaltrials.gov where it states it is seeking 75 volunteers for the trial at Guy’s drug research unit in London.

The company plans to test the volunteers over several months to monitor how long the vaccine remains effective and preliminary results are expected in January next year.

RELATED STORIES:
Roche’s Tamiflu suppresses Vietnam avian flu   Chemotherapy treatment suggested for bird flu patients   Mexico says tourist resorts safe from flu   France reinforces defenses against bird flu   New York City reports spike in flu   Cambodian girl dies from bird flu, Asia toll now 51   Myanmar asked to check bird flu report - FAO   Researchers say cut bird flu deaths by transfusions   Poor nations need help fighting bird flu   Two more bird flu cases confirmed in Indonesia   Bird flu a risk for US poultry exports   Fear arises that virus will mutate

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]